MBA III - Annovis Bio Chief Officer
| ANVS Stock | USD 7.28 0.57 8.49% |
Insider
MBA III is Chief Officer of Annovis Bio
| Age | 56 |
| Address | 101 Lindenwood Drive, Malvern, PA, United States, 19355 |
| Phone | (484) 875-3192 |
| Web | https://www.annovisbio.com |
Annovis Bio Management Efficiency
The company has return on total asset (ROA) of (1.5458) % which means that it has lost $1.5458 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.967) %, meaning that it created substantial loss on money invested by shareholders. Annovis Bio's management efficiency ratios could be used to measure how well Annovis Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 7.61 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (5.23). At this time, Annovis Bio's Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 53.7 M in 2024, despite the fact that Return On Tangible Assets are likely to grow to (5.23).Similar Executives
| Showing other executives | INSIDER Age | ||
| Kenneth MD | Cue Biopharma | 64 | |
| JD MSc | Cue Biopharma | 61 | |
| DVM MS | Lantern Pharma | N/A | |
| Julie Bockenstette | Acumen Pharmaceuticals | N/A | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| MD MPH | Anavex Life Sciences | N/A | |
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 52 | |
| Mark Vignola | Terns Pharmaceuticals | 46 | |
| James CFA | Novavax | 58 | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| John III | Novavax | 58 | |
| Glenn Mattes | Tff Pharmaceuticals | 67 | |
| Sandra Esq | Immunome | 51 | |
| MSc MBA | Inozyme Pharma | 52 | |
| Laxminarayan Bhat | Reviva Pharmaceuticals Holdings | 59 | |
| Purnanand Sarma | Immunome | 59 | |
| Stefan Riley | Inozyme Pharma | N/A | |
| MBA MS | Anavex Life Sciences | 56 | |
| Russell MS | Acumen Pharmaceuticals | 66 | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| Janice Hitchcock | Acumen Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -5.97 | ||||
| Return On Asset | -1.55 |
Annovis Bio Leadership Team
Elected by the shareholders, the Annovis Bio's board of directors comprises two types of representatives: Annovis Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Annovis. The board's role is to monitor Annovis Bio's management team and ensure that shareholders' interests are well served. Annovis Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Annovis Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hilda Maibach, Senior Statistics | ||
| Michael Hoffman, Independent Director Chairman of the Board | ||
| Jeffrey McGroarty, Chief Financial Officer | ||
| RAC MS, Senior Operations | ||
| Claudine Bruck, Independent Director | ||
| Maria Maccecchini, President, Chief Executive Officer, Founder, Director | ||
| MBA III, Chief Officer | ||
| Blake Jensen, Head Quality | ||
| Reid McCarthy, Independent Director | ||
| Cheng Fang, Senior Development | ||
| Melissa Gaines, Senior Operations | ||
| Mark White, Independent Director |
Annovis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Annovis Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.97 | ||||
| Return On Asset | -1.55 | ||||
| Current Valuation | 87.81 M | ||||
| Shares Outstanding | 13.8 M | ||||
| Shares Owned By Insiders | 20.40 % | ||||
| Shares Owned By Institutions | 8.83 % | ||||
| Number Of Shares Shorted | 1.39 M | ||||
| Price To Earning | (0.43) X | ||||
| Price To Book | 14.22 X | ||||
| EBITDA | (45.04 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Annovis Stock Analysis
When running Annovis Bio's price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.